Aeterna Zentaris Reports First Quarter 2024 Financial Results

Core Viewpoint - Aeterna Zentaris Inc. reported a net loss for Q1 2024 and is on track to complete the DETECT-trial and a merger with Ceapro Inc. in the upcoming quarters [1][3][11] Financial Summary - The company ended Q1 2024 with $29.5 million in cash and cash equivalents [2] - A net loss of $5.8 million was reported for Q1 2024, compared to a net loss of $4.3 million in Q1 2023, marking a $1.5 million increase in loss [3] - Total revenue decreased by $2.1 million in Q1 2024, primarily due to the termination of an agreement with Novo Nordisk Healthcare [3] Operating Expenses - Total operating expenses for Q1 2024 were $6.1 million, a slight decrease from $6.3 million in the same period of 2023 [4] - The decrease in operating expenses was attributed to a $1.4 million reduction in research and development expenses, offset by a $1.2 million increase in selling, general, and administrative expenses [4] Product Development - Aeterna is developing macimorelin (Macrilen; GHRYVELIN™) for diagnosing adult and childhood-onset growth hormone deficiencies [6][8] - The DETECT-trial is currently ongoing to evaluate macimorelin for childhood-onset growth hormone deficiency [1][6]